Deutsche Bank AG Has $11.70 Million Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Deutsche Bank AG lifted its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 54.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 145,242 shares of the company's stock after buying an additional 51,289 shares during the period. Deutsche Bank AG owned approximately 0.28% of PROCEPT BioRobotics worth $11,695,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Raleigh Capital Management Inc. acquired a new stake in PROCEPT BioRobotics in the fourth quarter valued at approximately $32,000. Thematics Asset Management purchased a new stake in PROCEPT BioRobotics during the 4th quarter worth $46,000. Signaturefd LLC lifted its holdings in PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after buying an additional 145 shares in the last quarter. IFP Advisors Inc acquired a new stake in shares of PROCEPT BioRobotics during the fourth quarter valued at about $58,000. Finally, Arcadia Investment Management Corp MI purchased a new stake in PROCEPT BioRobotics during the 4th quarter worth approximately $64,000. Institutional investors and hedge funds own 89.46% of the company's stock.

PROCEPT BioRobotics Stock Up 2.1%

NASDAQ:PRCT traded up $1.22 during trading hours on Monday, hitting $59.29. 708,661 shares of the company's stock traded hands, compared to its average volume of 816,900. The firm has a market cap of $3.28 billion, a P/E ratio of -30.40 and a beta of 1.10. PROCEPT BioRobotics Co. has a twelve month low of $47.04 and a twelve month high of $103.81. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The stock's fifty day moving average price is $55.22 and its two-hundred day moving average price is $71.77.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.04. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company had revenue of $69.16 million for the quarter, compared to analyst estimates of $65.39 million. During the same period in the prior year, the firm posted ($0.51) EPS. The business's revenue was up 55.5% compared to the same quarter last year. On average, research analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PRCT has been the topic of a number of recent research reports. Morgan Stanley reduced their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Bank of America dropped their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Friday, April 25th. Finally, Truist Financial dropped their price objective on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $90.00.

Insider Activity

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now owns 173,070 shares of the company's stock, valued at $9,875,374.20. This trade represents a 3.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the sale, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. The trade was a 0.67% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,455 shares of company stock valued at $368,322. Insiders own 6.60% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).